Harry W Herr1, Guido Dalbagni. 1. Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Abstract
PURPOSE: We define bacillus Calmette-Guerin (BCG) refractory, high risk, superficial bladder cancer. MATERIALS AND METHODS: A total of 93 patients received a 6-week induction course of BCG. They were evaluated for response after 3 and 6 months. Half of the patients received monthly maintenance BCG for 2 years and half did not. In both groups the initial responses to BCG at 3 and 6 months were correlated with subsequent tumor recurrence and progression. RESULTS: Of the 93 cases 57% were negative for tumor at 3 months and 43% had residual tumor resected. At 6 months 80% of the patients were tumor-free and 20% had persistent or recurrent tumor. Maintenance BCG did not decrease tumor recurrence further than induction BCG. Subsequent tumor-free interval during 24 months of followup were best predicted by response to BCG after 6 months. CONCLUSIONS: A minimum treatment and followup time of 6 months is required to identify high risk, superficial bladder tumors as truly BCG refractory.
PURPOSE: We define bacillus Calmette-Guerin (BCG) refractory, high risk, superficial bladder cancer. MATERIALS AND METHODS: A total of 93 patients received a 6-week induction course of BCG. They were evaluated for response after 3 and 6 months. Half of the patients received monthly maintenance BCG for 2 years and half did not. In both groups the initial responses to BCG at 3 and 6 months were correlated with subsequent tumor recurrence and progression. RESULTS: Of the 93 cases 57% were negative for tumor at 3 months and 43% had residual tumor resected. At 6 months 80% of the patients were tumor-free and 20% had persistent or recurrent tumor. Maintenance BCG did not decrease tumor recurrence further than induction BCG. Subsequent tumor-free interval during 24 months of followup were best predicted by response to BCG after 6 months. CONCLUSIONS: A minimum treatment and followup time of 6 months is required to identify high risk, superficial bladder tumors as truly BCG refractory.
Authors: Wassim Kassouf; Ashish M Kamat; Alexander Zlotta; Bernard H Bochner; Ronald Moore; Alan So; Jonathan Izawa; Ricardo A Rendon; Louis Lacombe; Armen G Aprikian Journal: Can Urol Assoc J Date: 2010-06 Impact factor: 1.862
Authors: Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black Journal: Can Urol Assoc J Date: 2015-10-13 Impact factor: 1.862
Authors: Daher C Chade; Ricardo C Borra; Ivan P Nascimento; Fabiola E Villanova; Luciana C C Leite; Enrico Andrade; Miguel Srougi; Kátia L Ramos; Priscila M Andrade Journal: J Exp Clin Cancer Res Date: 2008-11-28